Bildkälla: Stockfoto

Alzecure: Additional information from ACD856 Phase I trial Released - Redeye

Redeye gives a short comment on the ACD856 Phase I “MAD” data presented at the AAIC conference and reiterate our positive view of the drug candidate.

Redeye gives a short comment on the ACD856 Phase I “MAD” data presented at the AAIC conference and reiterate our positive view of the drug candidate.
Börsvärldens nyhetsbrev
ANNONSER